JP7817948B2 - がんを処置するための組成物および方法 - Google Patents

がんを処置するための組成物および方法

Info

Publication number
JP7817948B2
JP7817948B2 JP2022564548A JP2022564548A JP7817948B2 JP 7817948 B2 JP7817948 B2 JP 7817948B2 JP 2022564548 A JP2022564548 A JP 2022564548A JP 2022564548 A JP2022564548 A JP 2022564548A JP 7817948 B2 JP7817948 B2 JP 7817948B2
Authority
JP
Japan
Prior art keywords
cancer
cells
pharmaceutical composition
domain
chimeric binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022564548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523016A5 (https=
JPWO2021216956A5 (https=
JP2023523016A (ja
Inventor
ケレシュ，デイヴィッド
ヴァイス，サラ
マコーマック，スティーヴン
レイダー，クリストフ
ウェッターステン，ヒロミ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Beta Holdings LLC
Original Assignee
Alpha Beta Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Holdings LLC filed Critical Alpha Beta Holdings LLC
Publication of JP2023523016A publication Critical patent/JP2023523016A/ja
Publication of JP2023523016A5 publication Critical patent/JP2023523016A5/ja
Publication of JPWO2021216956A5 publication Critical patent/JPWO2021216956A5/ja
Application granted granted Critical
Publication of JP7817948B2 publication Critical patent/JP7817948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022564548A 2020-04-23 2021-04-23 がんを処置するための組成物および方法 Active JP7817948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
US63/014,550 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (4)

Publication Number Publication Date
JP2023523016A JP2023523016A (ja) 2023-06-01
JP2023523016A5 JP2023523016A5 (https=) 2024-04-26
JPWO2021216956A5 JPWO2021216956A5 (https=) 2024-04-26
JP7817948B2 true JP7817948B2 (ja) 2026-02-19

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564548A Active JP7817948B2 (ja) 2020-04-23 2021-04-23 がんを処置するための組成物および方法

Country Status (12)

Country Link
US (1) US20230140868A1 (https=)
EP (1) EP4110822A4 (https=)
JP (1) JP7817948B2 (https=)
KR (1) KR20230019424A (https=)
CN (1) CN115485301A (https=)
AU (1) AU2021261003A1 (https=)
BR (1) BR112022019939A2 (https=)
CA (1) CA3172092A1 (https=)
IL (1) IL296576A (https=)
MX (1) MX2022013207A (https=)
PH (1) PH12022553129A1 (https=)
WO (1) WO2021216956A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102423686B1 (ko) * 2019-01-10 2022-07-21 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
WO2020145669A1 (ko) 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer
CN118542937A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508656A (ja) 1997-03-12 2002-03-19 スミスクライン・ビーチャム・コーポレイション 抗−アルファベータ３ヒト化モノクローナル抗体
JP2002530108A (ja) 1998-11-24 2002-09-17 スミスクライン・ビーチャム・コーポレイション ヒト化モノクローナル抗体
JP2008510008A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト
JP2018535692A (ja) 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
BR112013026828A2 (pt) * 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
CA2881981A1 (en) * 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
BR112015023752B1 (pt) * 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
EP4353318A3 (en) * 2017-03-31 2024-07-17 The Regents of the University of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508656A (ja) 1997-03-12 2002-03-19 スミスクライン・ビーチャム・コーポレイション 抗−アルファベータ３ヒト化モノクローナル抗体
JP2002530108A (ja) 1998-11-24 2002-09-17 スミスクライン・ビーチャム・コーポレイション ヒト化モノクローナル抗体
JP2008510008A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト
JP2018535692A (ja) 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Tam SH. et al.，Antibodies，2017年，Vol. 6, No.3, 12，pp. 1-34
Wettersten HI. et al.，Cancer Res.，2019年，Vol. 79, No. 19，pp. 5048-5059

Also Published As

Publication number Publication date
BR112022019939A2 (pt) 2022-12-13
WO2021216956A1 (en) 2021-10-28
MX2022013207A (es) 2023-01-24
US20230140868A1 (en) 2023-05-11
IL296576A (en) 2022-11-01
EP4110822A1 (en) 2023-01-04
AU2021261003A1 (en) 2022-10-20
EP4110822A4 (en) 2024-04-10
CA3172092A1 (en) 2021-10-28
CN115485301A (zh) 2022-12-16
PH12022553129A1 (en) 2024-02-26
KR20230019424A (ko) 2023-02-08
JP2023523016A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7466221B2 (ja) 抗クローディン１８．２抗体およびその使用
JP7817948B2 (ja) がんを処置するための組成物および方法
EP3568415B1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
US10487150B2 (en) SIRP alpha-antibody fusion proteins
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
MD3535298T2 (ro) Anticorpi ai PD-1 și utilizări ale acestora
IL277863B1 (en) Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
CA3087166A1 (en) Antibodies to lilrb2
CN110545844A (zh) 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
KR20200130747A (ko) 항-pd-l1 항체 및 그것의 사용
TW201420600A (zh) 抗－間皮素結合蛋白質
CN102083861B (zh) 使用结合EphB4的人源化抗体的癌症治疗
WO2023056326A1 (en) Compositions and methods for treating cancer
KR102955590B1 (ko) 인간화 항-SIRPα 항체
HK40094578B (zh) 抗密蛋白18.2抗体及其用途
HK40094577B (zh) 抗密蛋白18.2抗体及其用途
HK40094578A (zh) 抗密蛋白18.2抗体及其用途
HK40094577A (zh) 抗密蛋白18.2抗体及其用途
WO2024040150A1 (en) Binding agents targeting gd2 and their use for treating cancer
CA2957531C (en) Sirp alpha-antibody fusion proteins
KR20260026018A (ko) 항-ccr8 항체 및 항-ccr8/ctla4 이중특이성 항체
HK40076107B (zh) 人源化、小鼠或嵌合抗cd47单克隆抗体
HK40087544A (zh) 改善与静脉内施用有关的抗体耐受性
NZ749019B2 (en) Anti-pd-l1 antibodies and uses thereof
HK1238573B (en) Sirp alpha-antibody fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260206

R150 Certificate of patent or registration of utility model

Ref document number: 7817948

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150